Clinical Trial Update: A Study to Evaluate Persistence of Immunity of PCV13 in Healthy Population Aged 2 Months，7 Months-5 Years [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating the persistence of immunity of PCV13 in healthy children aged 2 months to 5 years, completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumonia

Drugs mentioned

• PCV13 (pneumococcal conjugate vaccine 13-valent)

Snippet

Sponsor: Beijing Minhai Biotechnology Co., Ltd | Conditions: Pneumonia | Phase 4 | Status: COMPLETED